Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)
Akero Therapeutics, Inc. (Nasdaq: AKRO)*

Organization & Developments: Akero

Parents

2021: Akero Therapeutics: A NASH Pureplay With Differentiated Mid Stage Data
2022: Akero Therapeutics: A Promising NASH Innovator_seekingalpha.com
2022: Akero Therapeutics: Outstanding Data In NASH_seekingalpha.com
2022: Akero Therapeutics: What Is Making The Stock Tick_ seekingalpha.com
2022: Akero Therapeutics' Positive NASH Trial Results And Cash Raise_seekingalpha.com
2022: Mid-cap clinical-stage company developing treatments for metabolic diseases
2022: Updated: Akero says positive PhIIb data buck the gloomy NASH tide, but questions remain on safety front
2023: Akero Therapeutics: Contrarian Buy Opportunity As Stock Tanks On 'NASH Dash' Data
2024: Akero Therapeutics Advances in MASH Treatment Trials
2024: Akero Therapeutics Inc: Business Model, SWOT Analysis, and Competitors 2024
2024: Akero Therapeutics: Good Candidate For The MASH Basket
2024: Akero Therapeutics: Where This Potential MASH Play Stands Currently
2024: Akero: Phase 2b NASH Data Bodes Well For Phase 3 SYNCHRONY Program
2025: Akero says MASH drug reverses liver damage in study, doubling shares
2025: Akero: FGF21 Advancement For MASH Targeting Presses On With Key Developments
2025: Akero: Reversal Of Cirrhosis With EFX Is A 'First' In F4 MASH Patients
2025: Novo Nordisk Snaps Up MASH Player Akero For Up To $5.2 Billion
2025: Some Good MASH/NASH News From Akero Therapeutics